CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,Matthew Davids, MD, MMSc

Panelists provide an overview of the current first-line treatment options for chronic lymphocytic leukemia (CLL), discussing the role of BTK inhibitors and venetoclax plus obinutuzumab (CLL14), and explore the continued role of ibrutinib in the CLL treatment landscape.

EP: 1.Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

EP: 2.Clinical Implications and Unmet Needs in CLL BTKi Therapies

EP: 3.Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

EP: 4.Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

EP: 5.Future Directions and Research Priorities in BTKi Treatment Approaches

EP: 6.Latest Trends and Innovations in CLL and MCL Treatment

Now Viewing

EP: 7.CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

Provide an overview of the current landscape of first-line treatment options for CLL. What role do BTK inhibitors have in this landscape?

What continued role does ibrutinib have in the current CLL treatment landscape?